13.73

0.23% 0.0308

Syndax Pharmaceuticals Inc (SNDX)

Overview News Price History Option Chain Financials Discussions Forecast

Syndax Pharmaceuticals Inc stock is traded at $13.73, with a volume of 701.18K. It is up +0.23% in the last 24 hours and down -11.97% over the past month. Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Previous Close:

$13.70

Open:

$13.61

24h Volume:

701.18K

Relative Volume:

0.26

Market Cap:

$1.18B

Revenue:

$139.71M

Net Income/Loss:

$-209.36M

P/E Ratio:

-4.6388

EPS:

-2.96

Net Cash Flow:

$-160.60M

1W Performance:

+4.74%

1M Performance:

-11.97%

6M Performance:

+0.01%

1Y Performance:

-27.65%

1-Day Range:

$13.55

$14.36

1-Week Range:

$13.02

$14.36

52-Week Range:

$8.58

$22.50

Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile

Name

Syndax Pharmaceuticals Inc

Sector

Healthcare (1136)

Industry

Biotechnology (635)

Phone

781-419-1400

Address

730 THIRD AVENUE, NEW YORK, MA

Employee

184

Twitter

@syndax

Next Earnings Date

2025-03-03

Latest SEC Filings

SNDX's Discussions on Twitter

Compare SNDX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SNDX Syndax Pharmaceuticals Inc	13.74	1.18B	139.71M	-209.36M	-160.60M	-2.96
VRTX Vertex Pharmaceuticals Inc	423.52	109.11B	11.39B	3.64B	3.50B	13.99
REGN Regeneron Pharmaceuticals Inc	635.18	68.50B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	441.68	60.25B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	827.86	50.39B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	182.35	40.44B	447.02M	-1.18B	-868.57M	-6.1812

Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-16-25	Resumed	H.C. Wainwright	Buy
Sep-10-25	Resumed	Stifel	Buy
Sep-04-25	Resumed	Guggenheim	Buy
Aug-05-25	Reiterated	BTIG Research	Buy
Jul-10-25	Initiated	Goldman	Buy
Oct-24-24	Initiated	UBS	Buy
Jun-28-24	Initiated	Jefferies	Buy
Jan-31-24	Downgrade	Scotiabank	Sector Outperform → Sector Perform
Dec-22-23	Initiated	Mizuho	Buy
Oct-25-23	Initiated	BofA Securities	Buy
Oct-11-23	Initiated	Goldman	Buy
Jul-27-23	Initiated	Scotiabank	Sector Outperform
Jul-11-23	Initiated	Guggenheim	Buy
Apr-17-23	Resumed	BTIG Research	Buy
Jan-31-23	Initiated	Stifel	Buy
Jan-03-23	Initiated	JP Morgan	Overweight
Jul-28-22	Resumed	B. Riley Securities	Buy
Apr-11-22	Initiated	H.C. Wainwright	Buy
Feb-15-22	Initiated	Goldman	Buy
Jun-04-21	Resumed	Robert W. Baird	Outperform
May-25-21	Initiated	Citigroup	Buy
Feb-18-21	Initiated	B. Riley Securities	Buy
Dec-03-20	Initiated	Stifel	Buy
May-22-20	Upgrade	Citigroup	Neutral → Buy
May-22-20	Downgrade	H.C. Wainwright	Buy → Neutral
May-18-20	Downgrade	Citigroup	Buy → Neutral
May-11-20	Reiterated	H.C. Wainwright	Buy
Mar-04-20	Initiated	Barclays	Overweight
Jan-13-20	Reiterated	H.C. Wainwright	Buy
Mar-08-19	Reiterated	H.C. Wainwright	Buy
Jan-04-19	Initiated	Robert W. Baird	Outperform
Jan-05-18	Initiated	B. Riley FBR, Inc.	Buy
Mar-16-17	Initiated	FBR & Co.	Outperform
Mar-02-17	Initiated	Instinet	Buy
Oct-07-16	Initiated	Guggenheim	Buy
Mar-28-16	Initiated	Citigroup	Buy
Mar-28-16	Initiated	JMP Securities	Mkt Outperform
Mar-28-16	Initiated	Morgan Stanley	Overweight

View All

Syndax Pharmaceuticals Inc Stock (SNDX) Latest News

09:08 AM

Syndax (NASDAQ: SNDX) to present Revuforj and Niktimvo data in 23 ASH 2025 abstracts - Stock Titan

09:08 AM

03:20 AM

AlphaQuest LLC Sells 18,370 Shares of Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat

03:20 AM

01:41 AM

Applying Wyckoff theory to Syndax Pharmaceuticals Inc. stock2025 Price Action Summary & Free Long-Term Investment Growth Plans - newser.com

01:41 AM

01:19 AM

Detecting support and resistance levels for Syndax Pharmaceuticals Inc.Jobs Report & Verified Swing Trading Watchlist - newser.com

01:19 AM

Nov 02, 2025

Using Ichimoku Cloud for Syndax Pharmaceuticals Inc. technicalsJuly 2025 Recap & Technical Buy Zone Confirmations - newser.com

Nov 02, 2025

Leading vs lagging indicators on Syndax Pharmaceuticals Inc. performanceTrend Reversal & Risk Adjusted Buy/Sell Alerts - newser.com

Nov 02, 2025

Is Syndax Pharmaceuticals Inc. showing signs of accumulationMarket Volume Summary & AI Driven Stock Movement Reports - newser.com

Nov 02, 2025

Syndax Pharmaceuticals (SNDX) Q3 Earnings Preview: Key Expectati - GuruFocus

Nov 02, 2025

Kura Oncology's Ziftomenib Poised For Differentiation (NASDAQ:KURA) - Seeking Alpha

Nov 02, 2025

Is Syndax Pharmaceuticals Inc. stock reversal real or fake2025 Risk Factors & Daily Stock Trend Watchlist - newser.com

Nov 02, 2025

How risky is Syndax Pharmaceuticals Inc. stock nowJuly 2025 Recap & Free Technical Pattern Based Buy Signals - newser.com

Nov 02, 2025

Nov 01, 2025

Is Syndax Pharmaceuticals Inc. stock poised for growthJuly 2025 Reactions & Short-Term High Return Strategies - newser.com

Nov 01, 2025

Y Intercept Hong Kong Ltd Makes New Investment in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat

Nov 01, 2025

Oct 31, 2025

B. Riley Issues Optimistic Estimate for SNDX Earnings - MarketBeat

Oct 31, 2025